Effect of Two Transport Options on the Welfare of Two Genetic Lines of Organic Free Range Pullets in Switzerland

Simple Summary Animal welfare has been of increasing interest to consumers and producers of animal products in Europe. Issues during transport affect both the wellbeing and the productivity of livestock. This study was conducted to analyze two practice-oriented transport variants of organically mixed-held white and brown pullets. No significant difference could be found between the transport variants. Instead, we discovered clear differences between the two genetic pullet lines. Abstract The welfare of two genetic lines of organic layer hen pullets—H&N Super Nick (HNS) and H&N Brown Nick (HNB)—was compared during two commercial transport variants of 15 flocks of mixed-reared birds. Birds were either transported overnight (with a break in travel), or were transported direct to the layer farm (without a break in travel). Samples of feces were collected non-invasively from 25 birds of each genetic line per flock for each transport variant before transportation to evaluate baseline values of glucocorticoid metabolites, and at 0 h, 3 h, 6 h, 10 h, 24 h, 34 h, 48 h, 58 h, and 72 h after the end of transportation, to measure transportation and translocation stress. We assessed the fear toward humans with the touch test before transportation, and we checked the birds’ body condition by scoring the plumage condition and the occurrence of injuries. Body weight before and weight loss after transportation were determined, and ambient temperature was measured before, during, and after transportation. Stress investigations showed no significant differences between the transport variants (effect: −0.208; 95% confidence interval (CI): (−0.567; 0.163)). Instead, we discovered differences between the pullet lines (effect: −0.286; 95% CI: (−0.334; 0.238)). Weight loss was different between the transport variants (2.1 percentage points; 95% CI: (−2.6; −1.5)) and between the genetic lines, as HNB lost significantly less weight than HNS (0.5 percentage points; 95% CI: (0.3; 0.7)

Ginkgo biloba for the treatment of vitilgo vulgaris: an open label pilot clinical trial

<p>Abstract</p> <p>Background</p> <p>Vitiligo is a common hypopigmentation disorder with significant psychological impact if occurring before adulthood. A pilot clinical trial to determine the feasibility of an RCT was conducted and is reported here.</p> <p>Methods</p> <p>12 participants 12 to 35 years old were recruited to a prospective open-label pilot trial and treated with 60 mg of standardized <it>G. biloba </it>two times per day for 12 weeks. The criteria for feasibility included successful recruitment, 75% or greater retention, effectiveness and lack of serious adverse reactions. Effectiveness was assessed using the Vitiligo Area Scoring Index (VASI) and the Vitiligo European Task Force (VETF), which are validated outcome measures evaluating the area and intensity of depigmentation of vitiligo lesions. Other outcomes included photographs and adverse reactions. Safety was assessed by serum coagulation factors (platelets, PTT, INR) at baseline and week 12.</p> <p>Results</p> <p>After 2 months of recruitment, the eligible upper age limit was raised from 18 to 35 years of age in order to facilitate recruitment of the required sample size. Eleven participants completed the trial with 85% or greater adherence to the protocol. The total VASI score improved by 0.5 (P = 0.021) from 5.0 to 4.5, range of scale 0 (no depigmentation) to 100 (completely depigmented). The progression of vitiligo stopped in all participants; the total VASI indicated an average repigmentation of vitiligo lesions of 15%. VETF total vitiligo lesion area decreased 0.4% (P = 0.102) from 5.9 to 5.6 from baseline to week 12. VETF staging score improved by 0.7 (P = 0.101) from 6.6 to 5.8, and the VETF spreading score improved by 3.9 (P < 0.001)) from 2.7 to -1.2. There were no statistically significant changes in platelet count, PTT, or INR.</p> <p>Conclusions</p> <p>The criteria for feasibility were met after increasing the maximum age limit of the successful recruitment criterion; participant retention, safety and effectiveness criteria were also met. Ingestion of 60 mg of <it>Ginkgo biloba </it>BID was associated with a significant improvement in total VASI vitiligo measures and VETF spread, and a trend towards improvement on VETF measures of vitiligo lesion area and staging. Larger, randomized double-blind clinical studies are warranted and appear feasible.</p> <p>Trial Registration</p> <p>Clinical trials.gov registration number <a href="http://www.clinicaltrials.gov/ct2/show/NCT00907062">NCT00907062</a></p

Ginkgo biloba Extract in Alzheimer’s Disease: From Action Mechanisms to Medical Practice

Standardized extract from the leaves of the Ginkgo biloba tree, labeled EGb761, is one of the most popular herbal supplements. Numerous preclinical studies have shown the neuroprotective effects of EGb761 and support the notion that it may be effective in the treatment and prevention of neurodegenerative disorders such as Alzheimer’s disease (AD). Despite the preclinical promise, the clinical efficacy of this drug remains elusive. In this review, possible mechanisms underlying neuroprotective actions of EGb761 are described in detail, together with a brief discussion of the problem of studying this herb clinically to verify its efficacy in the treatment and prevention of AD. Moreover, various parameters e.g., the dosage and the permeability of the blood brain barrier (BBB), impacting the outcome of the clinical effectiveness of the extract are also discussed. Overall, the findings summarized in this review suggest that, a better understanding of the neuroprotective mechanisms of EGb761 may contribute to better understanding of the effectiveness and complexity of this herb and may also be helpful for design of therapeutic strategies in future clinical practice. Therefore, in future clinical studies, different factors that could interfere with the effect of EGb761 should be considered